Kai Qu
Impact in
- Cancer Research top 2%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Hepatology top 5%
Papers in
-
- Cancer-related molecular mechanisms research 11
- Hepatology 12
- Hepatocellular Carcinoma Treatment and Prognosis 7
- Co-authors
- Jingyao Zhang (25 shared papers)Ruixia Cui (13 shared papers)Yingmu Tong (11 shared papers)Yifan Jia (9 shared papers)Runchen Miao (13 shared papers)Yang Feng (5 shared papers)Chang Liu (10 shared papers)Xian Qin (17 shared papers)
- Journals
- Oxidative Medicine and Cellular Longevity (7 papers)Oncotarget (6 papers)ACS Applied Materials & Interfaces (5 papers)Aging (4 papers)Medicine (4 papers)
- Partner nations
- ChinaThailandUnited States
In The Last Decade
Kai Qu
126 papers receiving 4.1k citations
Kai Qu's Hit Papers
Peers
Comparison fields: 5 of 132
- Cancer Research 781
- Hepatology 205
- Molecular Biology 1.7k
- Rehabilitation 145
- Surgery 725
Countries citing papers authored by Kai Qu
This map shows the geographic impact of Kai Qu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kai Qu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kai Qu more than expected).
Fields of papers citing papers by Kai Qu
This network shows the impact of papers produced by Kai Qu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kai Qu. The network helps show where Kai Qu may publish in the future.
Co-authors
The 25 scholars most cited alongside Kai Qu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 133 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway Hit paper breakdown → | 2014 | 357 |
| 2 | 2020 | 275 | |
| 3 | 2020 | 229 | |
| 4 | 2018 | 149 | |
| 5 | 2022 | 109 | |
| 6 | 2017 | 106 | |
| 7 | 2021 | 102 | |
| 8 | 2015 | 92 | |
| 9 | 2019 | 90 | |
| 10 | 2015 | 89 | |
| 11 | 2013 | 89 | |
| 12 | 2022 | 88 | |
| 13 | 2022 | 86 | |
| 14 | 2015 | 81 | |
| 15 | 2022 | 72 | |
| 16 | Ulinastatin protects against acetaminophen-induced liver injury by alleviating ferroptosis via the SIRT1/NRF2/HO-1 pathway. | 2021 | 66 |
| 17 | 2017 | 66 | |
| 18 | 2017 | 65 | |
| 19 | 2017 | 57 | |
| 20 | 2019 | 54 |
About Kai Qu
Kai Qu is a scholar working on Cancer Research, Hepatology, Molecular Biology, Surgery and Oncology, having authored 133 papers that have together received 4.1k indexed citations. Recurring topics across this work include Liver Disease Diagnosis and Treatment (12 papers), Cancer-related molecular mechanisms research (11 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (9 papers), Nanoplatforms for cancer theranostics (9 papers), Circular RNAs in diseases (8 papers), Hepatocellular Carcinoma Treatment and Prognosis (7 papers), Advanced Nanomaterials in Catalysis (6 papers) and Extracellular vesicles in disease (6 papers). The work is most often cited by research in Cancer Research (781 citations), Hepatology (205 citations), Molecular Biology (1.7k citations), Rehabilitation (145 citations) and Surgery (725 citations). Kai Qu has collaborated with scholars based in China, Thailand and United States. Frequent co-authors include Jingyao Zhang, Ruixia Cui, Yingmu Tong, Yifan Jia, Runchen Miao, Yang Feng, Chang Liu, Xian Qin, Xinsen Xu and Yong Hong Wan. Their work appears in journals such as Oxidative Medicine and Cellular Longevity, Oncotarget, ACS Applied Materials & Interfaces, Aging and Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.